Neoplasm Proteins

"Neoplasm Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.

Descriptor ID	D009363
MeSH Number(s)	D12.776.624
Concept/Terms	Neoplasm Proteins Neoplasm Proteins Proteins, Neoplasm

Below are MeSH descriptors whose meaning is more general than "Neoplasm Proteins".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Neoplasm Proteins [D12.776.624]

Below are MeSH descriptors whose meaning is related to "Neoplasm Proteins".

Below are MeSH descriptors whose meaning is more specific than "Neoplasm Proteins".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasm Proteins" by people in this website by year, and whether "Neoplasm Proteins" was a major or minor topic of these publications.

Bar chart showing 163 publications over 29 distinct years, with a maximum of 12 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
1997	1	0	1
1998	1	1	2
1999	2	1	3
2001	3	0	3
2002	2	1	3
2003	4	5	9
2004	3	4	7
2005	3	5	8
2006	3	1	4
2007	3	3	6
2008	4	2	6
2009	6	3	9
2010	2	3	5
2011	2	1	3
2012	5	6	11
2013	7	1	8
2014	5	1	6
2015	6	2	8
2016	7	3	10
2017	3	1	4
2018	6	4	10
2019	9	3	12
2020	4	1	5
2021	4	2	6
2022	0	4	4
2023	0	4	4
2024	0	1	1
2025	0	3	3

Below are the most recent publications written about "Neoplasm Proteins" by people in Profiles.

Montes-Rodr?guez IM, Centeno-Girona H, P?rez-M?rtir SV, Rivera N, Cruz-Correa M. Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos. Cancer Med. 2025 Sep; 14(17):e71216.

View in: PubMed
Daniels MH, Castro J, Lee YT, Gotur D, Knockenhauer KE, Grigoriu S, Lockbaum GJ, Cheong JE, Lu C, Brennan D, Buker SM, Liu J, Yao S, Sparling BA, Sickmier EA, Ribich S, Blakemore SJ, Silver SJ, Boriack-Sjodin PA, Duncan KW, Copeland RA. Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9. J Med Chem. 2025 May 08; 68(9):9537-9554.

View in: PubMed
Castro J, Daniels MH, Brennan D, Johnston B, Gotur D, Lee YT, Knockenhauer KE, Lu C, Wu J, Nayak S, Collins C, Bansal R, Buker SM, Case A, Liu J, Yao S, Sparling BA, Sickmier EA, Silver SJ, Blakemore SJ, Boriack-Sjodin PA, Duncan KW, Ribich S, Copeland RA. A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. Cancer Res. 2025 Feb 17; 85(4):758-776.

View in: PubMed
Nelson BH, Hamilton P, Phung MT, Milne K, Harris B, Thornton S, Stevens D, Kalaria S, Singh K, Laumont CM, Moss E, Alimujiang A, Meagher NS, Bolithon A, Fereday S, Kennedy CJ, Hendley J, Ariyaratne D, Alsop K, Traficante N, Goode EL, Karnezis A, Shen H, Richardson J, McKinnonDeurloo C, Chase A, Grout B, Doherty JA, Harris HR, Cushing-Haugen KL, Anglesio M, Heinze K, Huntsman D, Talhouk A, Hanley GE, Alsop J, Jimenez-Linan M, Pharoah PD, Boros J, Brand AH, Harnett PR, Sharma R, Hecht JL, Sasamoto N, Terry KL, Karlan B, Lester J, Carney ME, Goodman MT, Hernandez BY, Wilkens LR, Behrens S, Turzanski Fortner R, Fasching PA, Bisinotto C, Candido Dos Reis FJ, Ghatage P, K?bel M, Elishaev E, Modugno F, Cook L, Le N, Gentry-Maharaj A, Menon U, Garc?a MJ, Rodriguez-Antona C, Farrington K, Kelemen LE, Kommoss S, Staebler A, Garsed DW, Brenton JD, Piskorz AM, Bowtell DD, DeFazio A, Ramus SJ, Pike MC, Pearce CL. Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer. J Clin Invest. 2024 Oct 29; 134(24).

View in: PubMed
McFadden M, Singh SK, Kinnel B, Varambally S, Singh R. The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer. J Ovarian Res. 2023 Nov 21; 16(1):220.

View in: PubMed
Alrajeh K, AlAzzeh O, Roman Y. The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing. Pharmacogenomics. 2023 05; 24(7):381-398.

View in: PubMed
AlAzzeh O, Roman YM. The frequency of rs2231142 in ABCG2 among Native Hawaiian and Pacific Islander subgroups: implications for personalized rosuvastatin dosing. Pharmacogenomics. 2023 02; 24(3):173-182.

View in: PubMed
Alrajeh K, Roman YM. The frequency of rs2231142 in ABCG2?among Asian subgroups: implications for personalized rosuvastatin dosing. Pharmacogenomics. 2023 01; 24(1):15-26.

View in: PubMed
Abou-Fadel J, Jiang X, Grajeda B, Padarti A, Ellis CC, Flores E, Cailing-De La O AD, Zhang J. CCM signaling complex (CSC) couples both classic and non-classic Progesterone receptor signaling. Cell Commun Signal. 2022 08 15; 20(1):120.

View in: PubMed
Beasley HK, Widatalla SE, Whalen DS, Williams SD, Korolkova OY, Namba C, Pratap S, Ochieng J, Sakwe AM. Identification of MAGEC2/CT10 as a High Calcium-Inducible Gene in Triple-Negative Breast Cancer. Front Endocrinol (Lausanne). 2022; 13:816598.

View in: PubMed

People

Explore

Similar Concepts

Top Journals